Mauro Ferrari Sells 8,750 Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director Mauro Ferrari sold 8,750 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $56.39, for a total transaction of $493,412.50. Following the transaction, the director directly owned 68,764 shares in the company, valued at $3,877,601.96. This trade represents a 11.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Arrowhead Pharmaceuticals Price Performance

Shares of Arrowhead Pharmaceuticals stock opened at $57.95 on Wednesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 4.86 and a current ratio of 4.86. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $9.57 and a 52-week high of $59.27. The company has a fifty day moving average of $40.14 and a 200-day moving average of $26.63. The stock has a market capitalization of $7.87 billion, a price-to-earnings ratio of -724.28 and a beta of 1.28.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. CWM LLC increased its position in Arrowhead Pharmaceuticals by 134.3% during the 1st quarter. CWM LLC now owns 4,401 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 2,523 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Arrowhead Pharmaceuticals during the first quarter valued at about $174,000. XTX Topco Ltd bought a new position in Arrowhead Pharmaceuticals in the first quarter worth about $133,000. Vanguard Group Inc. lifted its holdings in Arrowhead Pharmaceuticals by 8.4% in the first quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company’s stock worth $168,201,000 after buying an additional 1,018,273 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in Arrowhead Pharmaceuticals by 1.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,035,290 shares of the biotechnology company’s stock valued at $13,190,000 after acquiring an additional 17,570 shares in the last quarter. Institutional investors own 62.61% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on ARWR shares. B. Riley raised Arrowhead Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, October 8th. Chardan Capital reissued a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Monday. Royal Bank Of Canada raised their target price on shares of Arrowhead Pharmaceuticals from $45.00 to $52.00 and gave the stock an “outperform” rating in a report on Wednesday, November 19th. Finally, HC Wainwright upped their price target on shares of Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the company a “buy” rating in a report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $53.33.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.